Pulse Biosciences, Inc., a clinical-stage medical technology company, develops therapeutic tissue treatment platform based on its proprietary nano-pulse stimulation (NPS) technology. Its NPS is a non-thermal, precise, and focal drug-free tissue treatment technology that initiates cell death within treated tissue used in oncology, dermatology/aesthetics, minimally invasive, and veterinary applications. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was founded in 2014 and is headquartered in Hayward, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PLSE
CUSIPN/A
Phone510-906-4600
Debt
Debt-to-Equity RatioN/A
Current Ratio15.41
Quick Ratio15.41
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.81 per share
Price / Book5.10
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-25,560,000.00
Net MarginsN/A
Return on Equity-77.03%
Return on Assets-70.27%
Miscellaneous
Employees33
Outstanding Shares16,880,000
Market Cap$249.95
Pulse Biosciences (NASDAQ:PLSE) Frequently Asked Questions
What is Pulse Biosciences' stock symbol?
Pulse Biosciences trades on the NASDAQ under the ticker symbol "PLSE."
How were Pulse Biosciences' earnings last quarter?
Pulse Biosciences Inc (NASDAQ:PLSE) issued its quarterly earnings results on Tuesday, May, 8th. The company reported ($0.51) earnings per share (EPS) for the quarter. View Pulse Biosciences' Earnings History.
When is Pulse Biosciences' next earnings date?
What is the consensus analysts' recommendation for Pulse Biosciences?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulse Biosciences in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Who are some of Pulse Biosciences' key competitors?
Some companies that are related to Pulse Biosciences include K2M Group (KTWO), Tactile Systems Technology (TCMD), Cerus (CERS), SurModics (SRDX), AngioDynamics (ANGO), LeMaitre Vascular (LMAT), Anika Therapeutics (ANIK), Endologix (ELGX), Antares Pharma (ATRS), Neuronetics (STIM), GenMark Diagnostics (GNMK), Inovio Pharmaceuticals (INO), Orthopediatrics (KIDS), Utah Medical Products (UTMD) and MiMedx Group (MDXG).
Who are Pulse Biosciences' key executives?
Pulse Biosciences' management team includes the folowing people:
- Mr. Darrin R. Uecker, Pres, CEO & Director (Age 52)
- Mr. Brian B. Dow, CFO, Sr. VP of Fin. & Admin., Treasurer and Sec. (Age 49)
- Dr. Richard Nuccitelli Ph.D., Chief Science Officer
- Dr. Holly Hartman Ph.D., J.D., VP of Bus. Devel. & Corp. Strategy
- Mr. David Danitz, VP of Engineering
When did Pulse Biosciences IPO?
(PLSE) raised $20 million in an initial public offering (IPO) on Wednesday, May 18th 2016. The company issued 5,000,000 shares at $4.00 per share. MDB Capital Group and Feltl and Company acted as the underwriters for the IPO.
Has Pulse Biosciences been receiving favorable news coverage?
Media headlines about PLSE stock have trended somewhat positive this week, according to Accern. The research firm rates the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Pulse Biosciences earned a coverage optimism score of 0.09 on Accern's scale. They also assigned news articles about the company an impact score of 45.60 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Pulse Biosciences' major shareholders?
Pulse Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Silverleafe Capital Partners LLC (0.20%). Company insiders that own Pulse Biosciences stock include Maky Zanganeh, Mitchell E Levinson, Robert J Greenberg, Robert W Duggan and Thierry B Thaure. View Institutional Ownership Trends for Pulse Biosciences.
Which institutional investors are buying Pulse Biosciences stock?
PLSE stock was acquired by a variety of institutional investors in the last quarter, including Silverleafe Capital Partners LLC. Company insiders that have bought Pulse Biosciences stock in the last two years include Maky Zanganeh, Mitchell E Levinson and Robert W Duggan. View Insider Buying and Selling for Pulse Biosciences.
How do I buy shares of Pulse Biosciences?
Shares of PLSE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pulse Biosciences' stock price today?
One share of PLSE stock can currently be purchased for approximately $14.63.
How big of a company is Pulse Biosciences?
Pulse Biosciences has a market capitalization of $249.95 million. Pulse Biosciences employs 33 workers across the globe.
How can I contact Pulse Biosciences?
Pulse Biosciences' mailing address is 3957 POINT EDEN WAY, HAYWARD CA, 94545. The company can be reached via phone at 510-906-4600 or via email at [email protected]
MarketBeat Community Rating for Pulse Biosciences (NASDAQ PLSE)
MarketBeat's community ratings are surveys of what our community members think about Pulse Biosciences and other stocks. Vote "Outperform" if you believe PLSE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLSE will underperform the S&P 500 over the long term. You may vote once every thirty days.
